MediciNova, Inc. (MNOV) Stock Price & Analysis
MediciNova, Inc. (MNOV) closed at USD 1.45 on Thursday, October 15, 2026, down 1.36% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 1.47; the Oct 15, 2026 session ranged USD 1.45–1.53 on volume of 58,655 shares. Market capitalization is $71.37M, with a 52-week range of USD 1.17–3.9 (NGM). Source: Nexqual, retrieved October 16, 2026 at 05:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/MNOV.md
Key facts (MNOV)
- Analysts: Buy (mean 1.75 on a 1–5 scale) (4 analysts), mean target USD 8.25 (range 6–11).
- Total return with dividends: 1Y +16.0% vs S&P 500 +18.1%; 5Y -62.0% vs S&P 500 +85.1%.
- Next earnings: 2026-11-12, EPS estimate USD -0.06, revenue estimate $50K.
Analysts (MNOV)
Consensus Buy (mean 1.75 on a 1–5 scale), 4 analysts; mean target USD 8.25 (low 6, high 11).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-17 | Roth Capital | Initiated | Buy | $6 |
Total return (dividends reinvested) (MNOV)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | +16.0% | -62.0% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +16.1% | -17.6% |
| Volatility (annualized) | 80.5% | 60.4% |
| Max drawdown | -58.0% (Sep 2026→Oct 2026) | -69.6% (Oct 2021→Aug 2024) |
Key Statistics (as of October 16, 2026 at 05:22 UTC)
| Price | USD 1.45 |
|---|---|
| Change | ▼ 1.36% (down) |
| Previous Close | USD 1.47 |
| Open | USD 1.47 |
| Day Range | USD 1.45 – 1.53 |
| 52-Week Range | USD 1.17 – 3.9 |
| Volume | 58,655 shares |
| Market Cap | $71.37M |
| Exchange | NGM |
Technical Analysis (MNOV)
Nexqual's technical model rates MNOV "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:22 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 39.85 (neutral) |
| vs SMA50 | Below (USD 1.77) |
| MACD | -0.15 (negative) |
Analyst Ratings (MNOV)
Wall Street analysts rate MNOV "Buy" based on 4 analysts, with a mean price target of USD 8.25 (range USD 6–11), per Nexqual as of October 16, 2026 at 05:22 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 8.25 |
| High Target | USD 11 |
| Low Target | USD 6 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (MNOV)
| Next Earnings Date | 2026-11-12 |
|---|---|
| EPS Estimate | USD -0.06 |
| Revenue Estimate | $50,000 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.05 vs est -0.07 ▲ beat |
| 2026-03-31 | USD -0.05 vs est -0.07 ▲ beat |
| 2025-12-31 | USD -0.05 vs est -0.1 ▲ beat |
| 2025-09-30 | USD -0.06 vs est -0.12 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financials & Fundamentals (MNOV)
| Total Revenue | $920,481 |
|---|---|
| Revenue Growth (latest quarter, YoY) | +240.60% |
| Gross Margin | +37.75% |
| Operating Margin | -554.31% |
| Profit Margin | +0.00% |
| ROE | -25.56% |
| Debt / Equity | 0 |
| Current Ratio | 8.75 |
| Total Cash | $25.42M |
| Total Debt | $117,038 |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financial Health Score (MNOV)
Nexqual rates MediciNova, Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:22 UTC.
| Growth | Strong — Revenue +241% YoY (latest Q) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $25M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$9M (TTM) |
| Efficiency | Critical — ROE -26%, ROA -16.4% |
Ownership (MNOV)
| Insider Ownership | +2.86% |
|---|---|
| Institutional Ownership | +20.38% |
| Shares Outstanding | 49.22M |
| Float | 42.94M |
| Short % of Float | +0.71% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Leadership (MNOV)
MediciNova, Inc. is led by Yuichi Iwaki (age 75), Co-Founder, President, CEO & Chairman, per Nexqual as of October 16, 2026 at 05:22 UTC.
| Co-Founder, President, CEO & Chairman | Yuichi Iwaki (age 75) |
|---|---|
| Senior VP, Chief Medical Officer & Director | Kazuko Matsuda M.D., M.P.H. (age 59) |
| CFO & Principal Financial Officer | Jason J. Kruger (age 47) |
Major Backers & Investors (MNOV)
Notable institutional backers of MediciNova, Inc. include Essex Woodlands Management Inc., Citigroup Inc., Fidelity, according to Nexqual as of October 16, 2026 at 05:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Essex Woodlands Management Inc. | 2.25% |
| Citigroup Inc. | 1.29% |
| Fidelity | 0.88% |
| UBS Group AG | 0.45% |
| Renaissance Technologies | 0.42% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 3.05% |
| BlackRock | 1.85% |
| Geode Capital | 1.1% |
| State Street | 0.39% |
| Northern Trust | 0.29% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt